|
Abnormal behavior
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
Asymptomatic PINK1 and LRRK2 MC also revealed smaller GMV in the hippocampal region, which might play a role in the observed psychiatric disorders.
|
20483373 |
2010 |
|
Abnormal behavior
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
In contrast, expression of the GTP binding defective mutant, K1347A, or knockout of the C. elegans LRRK2 homolog, LRK-1, prevents the LRRK2-induced neurodegeneration and behavioral abnormalities.
|
20382224 |
2010 |
|
Abnormal behavior
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
Consistently, LRRK2 p.G2019S rats do not develop overt neurodegeneration; however, they do exhibit behavioral abnormalities.
|
25000966 |
2014 |
|
Abnormal male sexual function
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Acute myocardial infarction
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Five LRRK2 G2019S carriers were identified, of whom 4 had Parkinson disease (clinically and pathologically confirmed), and the fifth was a control subject who died at age 68 years after an acute myocardial infarction with no evidence of neurodegenerative abnormalities.
|
16966501 |
2006 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Finally, SNTG1 and LRRK2 might be important in LUAD and LUSC, respectively.
|
30549039 |
2019 |
|
Agitation
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Agitation, CTCAE 3.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Agitation, CTCAE 5.0
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Akinesia
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Alzheimer disease, familial, type 3
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Investigation of the leucine-rich repeat kinase 2 (LRRK2) gene in late-onset Alzheimer's disease (AD) patients to screen for the G2019S mutation, which is common in Parkinson's cases.
|
17846883 |
2007 |
|
Alzheimer Disease, Late Onset
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Investigation of the leucine-rich repeat kinase 2 (LRRK2) gene in late-onset Alzheimer's disease (AD) patients to screen for the G2019S mutation, which is common in Parkinson's cases.
|
17846883 |
2007 |
|
Alzheimer Disease, Late Onset
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Co-occurrence of sporadic parkinsonism and late-onset Alzheimer's disease in a Brazilian male with the LRRK2 p.G2019S mutation.
|
19072560 |
2008 |
|
Alzheimer Disease, Late Onset
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Nevertheless, these observations together with new information about the Lrrk2 critical multifunctionality do not rule out the possible influence of other variants within LRRK2 in AD, so that other screenings focusing in the whole extension of the LRRK2 using larger sized confirmed AD sample are urgently needed.
|
19822953 |
2009 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In light of recent findings about the wide role of LRRK2 under normal and pathological conditions, it is tempting to speculate that LRRK2 mutations might play an upstream influence on the etiology of not just PD but also several alpha-synuclein and tau pathologies, including AD.
|
19072560 |
2008 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We screened the most common LRRK2 mutation (p.G2019S) in a series of 180 consecutive patients clinically diagnosed with Alzheimer Disease (AD).
|
19822953 |
2009 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Such suggestions are relevant mainly for people at putatively high risk of developing AD (i.e., older adults with mild cognitive impairment subtypes) or PD (i.e., older adults with either Mild Parkinsonian signs or LRRK2 G2019S mutation).
|
28588547 |
2017 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Abundant Aβ pathology can also be found in LRRK2 mutation carriers and is consistent with comorbid AD pathology.
|
31733655 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
A review of the available data and our results indicate that full-length Lrrk2 is not a major component of Lewy bodies in LBDs, and of hyper-phosphorylated tau inclusions in AD and tauopathies.
|
19142648 |
2009 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
Pathway enrichment analysis revealed viruses shared Oxidative Stress Defense System and LRRK2 pathways with AD and PD, respectively.
|
31217489 |
2019 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The results showed that LRRK2 variants (p.R1628P, p.G2385R, p.N551K, p.G2019S, and p.I2020T) were not associated with the risk of AD and were not a common cause of AD in populations.
|
31038182 |
2019 |
|
Alzheimer's Disease
|
0.100 |
Biomarker
|
disease |
BEFREE |
To look for possible common pathogenic mechanisms underlying age-related neurodegeneration in AD and PD, we employed genetic approaches to investigate systematically the roles of these gene products (e.g. presenilins (PS) for AD; Parkin, DJ-1, PINK1 and LRRK2 for PD) in the mouse brain, especially in neural circuits that are particularly vulnerable in AD or PD.
|
20173332 |
2010 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
LRRK2 variant associated with Alzheimer's disease.
|
20018409 |
2011 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Here, in order to discover potential AD-related loci, we investigated the association between late-onset AD (LOAD) susceptibility and nine single-nucleotide polymorphisms (SNPs) (rs11724635 of BST1, rs12637471 of MCCC1, rs15553999 of TMEM229, rs17649553 of MAPT, rs34311866 of TMEM175-GAK-DGKQ, rs356182 of SNCA, rs6430538 of ACMSD-TMEM163, rs76904798 of LRRK2 and rs823118 of RAB7L1-NUCKS1) which were reported to have genome-wide significant associations with PD risk in a recent Genome Wide Association Study performed among white population.
|
26738859 |
2017 |
|
Alzheimer's Disease
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Mutations in leucine-rich repeat kinase 2 gene (LRRK2) have been associated with idiopathic Parkinson's disease (PD), as well as pleomorphic neurodegenerative pathology, including Alzheimer's disease.
|
16632201 |
2006 |